Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02528721 · ClinicalTrials.gov registry record · Phase 3
Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
A Phase 3 study, sponsored by Meridian Bioscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 282
- Enrollment target
NCT02528721 is a Phase 3 study that has completed, run by Meridian Bioscience. The registered enrollment target is 282 participants.
The verdict
NCT02528721, a Phase 3 study, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 282 participants
- Enrollment target
Study Summary
The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori infection in adult patients and its results will be compared to biopsy results.
Interventions
- DEVICE Dual Mode BreathID Hp System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02528721
The ClinicalTrials.gov registry entry for NCT02528721 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dual Mode BreathID Hp System is the first listed.
NCT02528721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02528721 about?
NCT02528721 is a clinical study titled "Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection". The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori infection in adult patients and its results will be compared to biopsy result...
What is the current status of trial NCT02528721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 282 participants. The study started on 2015-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02528721?
The interventions under investigation include: Dual Mode BreathID Hp System (DEVICE).
Who is sponsoring clinical trial NCT02528721?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.